Gossamer Bio (GOSS) Expected to Post Quarterly Earnings on Wednesday

Gossamer Bio (NASDAQ:GOSS) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Gossamer Bio to post earnings of ($3.9340) per share and revenue of $12.16 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Gossamer Bio Stock Up 6.8%

GOSS opened at $9.77 on Wednesday. Gossamer Bio has a 12-month low of $8.29 and a 12-month high of $309.60. The firm’s fifty day moving average price is $11.36 and its 200 day moving average price is $45.82.

Wall Street Analyst Weigh In

GOSS has been the topic of several research analyst reports. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Chardan Capital reissued a “buy” rating on shares of Gossamer Bio in a report on Monday. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Finally, Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a report on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Gossamer Bio currently has an average rating of “Hold” and a consensus target price of $256.00.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.